WO2018139562A1 - 心筋症、陳旧性心筋梗塞および慢性心不全の治療薬 - Google Patents
心筋症、陳旧性心筋梗塞および慢性心不全の治療薬 Download PDFInfo
- Publication number
- WO2018139562A1 WO2018139562A1 PCT/JP2018/002373 JP2018002373W WO2018139562A1 WO 2018139562 A1 WO2018139562 A1 WO 2018139562A1 JP 2018002373 W JP2018002373 W JP 2018002373W WO 2018139562 A1 WO2018139562 A1 WO 2018139562A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cardiomyopathy
- peptide
- amino acid
- acid sequence
- cardiac
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present application relates to a pharmaceutical composition for preventing and / or treating cardiomyopathy, old myocardial infarction and chronic heart failure, comprising a fragment peptide of HMGB1 protein.
- Cardiomyopathy is defined as “myocardial disease accompanied by cardiac dysfunction”, often accompanied by cardiac structural abnormalities such as cardiac enlargement, myocardial cell hypertrophy, and myocardial fibrosis. Although secondary cardiomyopathy may be improved by treatment of the causative disease, there is still no curative treatment for idiopathic cardiomyopathy.
- Myocardial infarction which causes myocardial necrosis due to coronary artery occlusion, is a major underlying disease of heart disease (1st in the US and 2nd in Japan), which is the top cause of death in developed countries.
- heart disease (1st in the US and 2nd in Japan)
- progress in diagnostics, catheterization, and coronary artery bypass surgery has improved the results of acute treatment, cardiac enlargement and cardiac hypertrophy in patients with extensive infarction, severe reperfusion injury, and missed treatment opportunities In many cases, chronic heart failure develops.
- Non-patent Document 1 When chronic heart failure due to cardiomyopathy or old myocardial infarction becomes serious, existing treatments for chronic heart failure (ACE inhibitors, ⁇ -blockers, etc.) do not provide sufficient improvement and require heart transplantation There are cases where However, the transplant waiting period in Japan is as long as about 3 years (Non-patent Document 1), and there are many cases in which complications such as cerebral infarction and device infection occur during the waiting period. In addition, even after receiving a heart transplantation, there are problems such as increased risk of infection due to side effects of immunosuppressive agents that need to be continued thereafter, and complications such as coronary artery lesions. The survival rate is about 50% (Non-patent Document 2). Under such circumstances, it is desired to develop a new therapeutic agent for cardiomyopathy and old myocardial infarction and chronic heart failure resulting therefrom.
- ACE inhibitors ACE inhibitors, ⁇ -blockers, etc.
- Non-patent Document 3 and Patent Document 1 transplantation of a cell sheet requires a thoracotomy, which places a heavy burden on the patient and cannot be applied to patients who are difficult to operate due to factors such as aging.
- HMGB1 High mobility group box 1
- cardiomyopathy generally does not cause this phenomenon. It is characterized by slow progression of structural abnormalities such as fibrosis, and the pathological conditions of the two differ greatly.
- necrosis and inflammation of myocardial cells have converged, and heart enlargement and cardiac hypertrophy progress. Therefore, it was unclear whether the fragment peptide of HMGB1 protein exerted a therapeutic effect on cardiomyopathy and old myocardial infarction.
- the present application aims to provide a novel pharmaceutical effective for the prevention and / or treatment of cardiomyopathy and old myocardial infarction and chronic heart failure resulting therefrom.
- Another object of the present application is to provide a novel pharmaceutical effective for the prevention and / or treatment of heart diseases accompanied by structural abnormalities and / or dysfunctions of the heart.
- HMGB1 fragment peptide having a specific amino acid sequence has improved cardiac function, cardiac structural abnormalities (cardiomyocytes) in an animal model of dilated cardiomyopathy. It has been found that it has an effect of suppressing hypertrophy and myocardial fibrosis and promoting angiogenesis.
- the present inventors have also found that the specific HMGB1 fragment peptide improves cardiac function, cardiac structural abnormalities (heart expansion, cardiomyocyte hypertrophy and It has been found that it has the effect of suppressing myocardial fibrosis and promoting angiogenesis.
- the present application provides a pharmaceutical composition for the prevention and / or treatment of cardiomyopathy and old myocardial infarction and chronic heart failure resulting therefrom, comprising the specific HMGB1 fragment peptide.
- the specific HMGB1 fragment peptide suppresses cardiac structural abnormality and / or dysfunction in cardiomyopathy, and suppresses cardiac structural abnormality and dysfunction in old myocardial infarction. Therefore, the present application provides a pharmaceutical composition for the prevention and / or treatment of heart disease associated with cardiac structural abnormality and / or dysfunction, containing the specific HMGB1 fragment peptide.
- composition for prevention and / or treatment of heart disease accompanied by structural abnormality and / or dysfunction of heart, comprising the substance described in any one of (a) to (c) below (hereinafter referred to as substance A)
- substance A Pharmaceutical composition: (A) an HMGB1 fragment peptide comprising the amino acid sequence set forth in SEQ ID NO: 1; (B) a peptide comprising an amino acid sequence in which one or more amino acids are substituted, deleted, inserted or added in the amino acid sequence set forth in SEQ ID NO: 1, and having an activity of stimulating cell migration; c) A peptide comprising an amino acid sequence having about 80% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 1 and having an activity of stimulating cell migration.
- the pharmaceutical composition according to [1], wherein the heart disease accompanied by an abnormal cardiac structure and / or functional disorder is cardiomyopathy.
- the pharmaceutical composition according to [2], wherein the cardiomyopathy is idiopathic cardiomyopathy.
- the pharmaceutical composition according to [3], wherein the idiopathic cardiomyopathy is selected from the group consisting of dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy.
- the pharmaceutical composition according to [2], wherein the cardiomyopathy is secondary cardiomyopathy.
- Secondary cardiomyopathy is caused by ischemic cardiomyopathy, hypertensive cardiomyopathy, valvular cardiomyopathy, drug-induced cardiomyopathy, alcoholic cardiomyopathy, mitochondrial cardiomyopathy, cardiomyopathy due to cardiac sarcoidosis, cardiac amyloidosis
- the pharmaceutical composition according to [5] selected from the group consisting of cardiomyopathy, cardiomyopathy due to myocarditis, cardiomyopathy due to muscular dystrophy, cardiomyopathy due to cardiac Fabry disease, and perinatal cardiomyopathy object.
- [7] [1]
- the pharmaceutical composition according to [1] wherein the heart disease accompanied by abnormal heart structure and / or dysfunction is old myocardial infarction.
- a pharmaceutical composition containing substance A for preventing and / or treating chronic heart failure caused by cardiomyopathy or old myocardial infarction comprising a pharmaceutical composition for suppressing a cardiac structural abnormality selected from the group consisting of cardiac enlargement, cardiomyocyte hypertrophy and myocardial fibrosis, comprising a substance A in a patient with cardiomyopathy or old myocardial infarction.
- a pharmaceutical composition for preventing and / or treating cardiomyopathy selected from the group consisting of dilated cardiomyopathy, ischemic cardiomyopathy and hypertensive cardiomyopathy, comprising substance A.
- the pharmaceutical composition according to [10] wherein the ischemic cardiomyopathy is caused by old myocardial infarction.
- a pharmaceutical composition for prevention and / or treatment of chronic heart failure caused by cardiomyopathy selected from the group consisting of dilated cardiomyopathy, ischemic cardiomyopathy and hypertensive cardiomyopathy, comprising substance A.
- cardiomyopathy selected from the group consisting of dilated cardiomyopathy, ischemic cardiomyopathy and hypertensive cardiomyopathy, comprising substance A.
- ischemic cardiomyopathy is caused by old myocardial infarction.
- the pharmaceutical composition according to [12] wherein the chronic heart failure is caused by dilated cardiomyopathy or ischemic cardiomyopathy.
- the pharmaceutical composition according to [14] wherein the chronic heart failure resulting from dilated cardiomyopathy or ischemic cardiomyopathy is HFrEF.
- [16] [12] The pharmaceutical composition according to [12], wherein the chronic heart failure is caused by hypertensive cardiomyopathy.
- [17] [16] The pharmaceutical composition according to [16], wherein the chronic heart failure resulting from hypertensive cardiomyopathy is HFpEF.
- [A2] The method according to [A1], wherein the heart disease accompanied by cardiac structural abnormality and / or dysfunction is cardiomyopathy.
- cardiomyopathy is idiopathic cardiomyopathy.
- idiopathic cardiomyopathy is selected from the group consisting of dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy.
- cardiomyopathy is secondary cardiomyopathy.
- Secondary cardiomyopathy is caused by ischemic cardiomyopathy, hypertensive cardiomyopathy, valvular cardiomyopathy, drug-induced cardiomyopathy, alcoholic cardiomyopathy, mitochondrial cardiomyopathy, cardiomyopathy due to cardiac sarcoidosis, cardiac amyloidosis
- the method according to [A5] which is selected from the group consisting of cardiomyopathy, cardiomyopathy due to myocarditis, cardiomyopathy due to muscular dystrophy, cardiomyopathy due to cardiac Fabry disease, and perinatal cardiomyopathy.
- the method according to [A1] wherein the heart disease accompanied by abnormal heart structure and / or dysfunction is old myocardial infarction.
- a method for preventing and / or treating chronic heart failure resulting from cardiomyopathy or old myocardial infarction comprising a step of administering an effective amount of substance A to a subject.
- a method for suppressing a cardiac structural abnormality selected from the group consisting of cardiac enlargement, cardiomyocyte hypertrophy and myocardial fibrosis in a patient with cardiomyopathy or old myocardial infarction comprising a step of administering an effective amount of substance A to a subject .
- a method for preventing and / or treating cardiomyopathy selected from the group consisting of dilated cardiomyopathy, ischemic cardiomyopathy and hypertensive cardiomyopathy comprising the step of administering an effective amount of substance A to a subject.
- Substance A for use in the prevention and / or treatment of heart disease associated with cardiac structural abnormalities and / or dysfunctions.
- the cardiomyopathy is idiopathic cardiomyopathy.
- the idiopathic cardiomyopathy is selected from the group consisting of dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy.
- Substance A according to [B2] wherein the cardiomyopathy is secondary cardiomyopathy.
- Secondary cardiomyopathy is caused by ischemic cardiomyopathy, hypertensive cardiomyopathy, valvular cardiomyopathy, drug-induced cardiomyopathy, alcoholic cardiomyopathy, mitochondrial cardiomyopathy, cardiomyopathy due to cardiac sarcoidosis, cardiac amyloidosis Selected from the group consisting of cardiomyopathy, cardiomyopathy due to myocarditis, cardiomyopathy due to muscular dystrophy, cardiomyopathy due to cardiac Fabry disease, and peripartum cardiomyopathy, substance A according to [B5] .
- the substance A according to [B1] wherein the heart disease accompanied by abnormal heart structure and / or dysfunction is old myocardial infarction.
- Substance A for use in the prevention and / or treatment of chronic heart failure resulting from cardiomyopathy or old myocardial infarction.
- Substance A for use in suppressing cardiac structural abnormalities selected from the group consisting of cardiac enlargement, cardiomyocyte hypertrophy and myocardial fibrosis in patients with cardiomyopathy or old myocardial infarction.
- Substance A for use in the prevention and / or treatment of cardiomyopathy selected from the group consisting of dilated cardiomyopathy, ischemic cardiomyopathy and hypertensive cardiomyopathy.
- Substance A according to [B10] wherein ischemic cardiomyopathy results from old myocardial infarction.
- cardiomyopathy selected from the group consisting of dilated cardiomyopathy, ischemic cardiomyopathy and hypertensive cardiomyopathy.
- the ischemic cardiomyopathy is caused by old myocardial infarction.
- the chronic heart failure is caused by dilated cardiomyopathy or ischemic cardiomyopathy.
- Substance A according to [B14] wherein the chronic heart failure resulting from dilated cardiomyopathy or ischemic cardiomyopathy is HFrEF.
- [C6] Secondary cardiomyopathy is caused by ischemic cardiomyopathy, hypertensive cardiomyopathy, valvular cardiomyopathy, drug-induced cardiomyopathy, alcoholic cardiomyopathy, mitochondrial cardiomyopathy, cardiomyopathy due to cardiac sarcoidosis, cardiac amyloidosis
- [C8] Use of substance A in the manufacture of a medicament for the prevention and / or treatment of chronic heart failure resulting from cardiomyopathy or old myocardial infarction.
- [C9] Use of substance A in the manufacture of a medicament for inhibiting cardiac structural abnormalities selected from the group consisting of cardiac enlargement, cardiomyocyte hypertrophy and myocardial fibrosis in patients with cardiomyopathy or old myocardial infarction.
- [C10] Use of substance A in the manufacture of a medicament for the prevention and / or treatment of cardiomyopathy selected from the group consisting of dilated cardiomyopathy, ischemic cardiomyopathy and hypertensive cardiomyopathy.
- cardiomyopathy selected from the group consisting of dilated cardiomyopathy, ischemic cardiomyopathy and hypertensive cardiomyopathy.
- LVEF Left ventricular ejection fraction
- LPDd left ventricular end-diastolic diameter
- LPDs left ventricular end-systolic diameter
- FIG. 2 is a photograph showing the results of PAS staining of a myocardial tissue section, and a graph showing the short diameter of cardiomyocytes. It is a photograph which shows the result of the immuno-staining using the antibody with respect to PDGFR (alpha) and CD29.
- PDGFR ⁇ green
- CD29 red
- DAPI blue
- RQ Relative amount. It is a photograph which shows the observation result of the cardiac muscle cell by an electron microscope.
- LVEF left ventricular ejection fraction
- PDGFR ⁇ green, CD105: red, DAPI: blue. Arrows indicate double-positive cells of PDGFR ⁇ and CD105, and broken lines indicate infarct boundaries. It is a fluorescence immuno-staining image of the infarct boundary part of HMGB1 peptide (1-44) group and PBS group. PDGFR ⁇ : green, CD90: red, DAPI: blue. Arrows indicate double positive cells of PDGFR ⁇ and CD90, and broken lines indicate infarct boundaries. It is a graph which shows the heart weight at the time of 15 weeks of age. It is a graph which shows transition of LVAWd from the age of 6 weeks to the age of 15 weeks (however, measurement is not performed at 9 and 14 weeks of age).
- the present application provides a pharmaceutical composition for the prevention and / or treatment of heart disease associated with cardiac structural abnormality and / or dysfunction, comprising an HMGB1 fragment peptide comprising the amino acid sequence set forth in SEQ ID NO: 1.
- cardiac structural abnormalities include, but are not limited to, cardiac enlargement, cardiomyocyte hypertrophy, myocardial fibrosis, and the like.
- the structural abnormality of the heart is selected from the group consisting of cardiac enlargement, cardiomyocyte hypertrophy and myocardial fibrosis.
- cardiac dysfunction refers to a pump function disorder that the heart takes in and pumps blood, and includes contractile dysfunction and diastolic dysfunction.
- the cardiac dysfunction is selected from the group consisting of systolic dysfunction and diastolic dysfunction.
- the cardiac dysfunction is selected from the group consisting of ventricular contractility and diastolic dysfunction.
- the cardiac dysfunction is selected from the group consisting of left ventricular contractility and diastolic dysfunction.
- the present application provides a pharmaceutical composition for the prevention and / or treatment of cardiomyopathy, comprising an HMGB1 fragment peptide comprising the amino acid sequence set forth in SEQ ID NO: 1.
- cardiomyopathy refers to myocardial disease accompanied by cardiac dysfunction.
- cardiomyopathy is accompanied by abnormalities in the structure of the heart such as cardiac enlargement, cardiomyocyte hypertrophy, and myocardial fibrosis.
- Cardiomyopathy which has no obvious cause such as hypertension or coronary artery disease, and where the myocardium has the head of the lesion is called idiopathic cardiomyopathy, and is secondary to any cause or related to systemic disease It is called cardiomyopathy.
- Idiopathic cardiomyopathy includes, but is not limited to, dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and unclassifiable cardiomyopathy.
- “Dilated cardiomyopathy” is a disease characterized by left ventricular enlargement and left ventricular systolic dysfunction, which is not accompanied by abnormal load conditions (hypertension or valvular disease) and coronary artery disease that can cause diffuse contractile dysfunction.
- Secondary cardiomyopathy includes ischemic cardiomyopathy, hypertensive cardiomyopathy, valvular cardiomyopathy, drug-induced cardiomyopathy, alcoholic cardiomyopathy, mitochondrial cardiomyopathy, cardiomyopathy caused by cardiac sarcoidosis, and cardiac amyloidosis
- Examples include, but are not limited to, cardiomyopathy caused, cardiomyopathy caused by myocarditis, cardiomyopathy caused by muscular dystrophy, cardiomyopathy caused by cardiac Fabry disease, and perinatal cardiomyopathy.
- the cardiomyopathy due to muscular dystrophy is cardiomyopathy due to Duchenne, Becker or Emery-Dreifuss muscular dystrophy.
- ischemic cardiomyopathy refers to a disease exhibiting cardiac expansion and impaired myocardial contractility due to ischemic heart disease (old myocardial infarction or angina). Since the HMGB1 fragment peptide has the effect of suppressing cardiac expansion and the effect of improving myocardial contractility, it can prevent and / or treat ischemic cardiomyopathy. In one embodiment, the ischemic cardiomyopathy is due to old myocardial infarction.
- hypertensive cardiomyopathy refers to a disease exhibiting cardiomyocyte hypertrophy and cardiac dysfunction (diastolic dysfunction or contractile dysfunction) due to hypertension. Since HMGB1 fragment peptide can suppress cardiomyocyte hypertrophy caused by hypertension, it can prevent and / or treat hypertensive cardiomyopathy.
- pharmaceutical composition is used interchangeably with “medicine”, “drug” or “pharmaceutical composition”.
- the present application provides a pharmaceutical composition for the treatment of old myocardial infarction, comprising an HMGB1 fragment peptide comprising the amino acid sequence set forth in SEQ ID NO: 1.
- old myocardial infarction means a state in which at least 30 days have elapsed since the onset of myocardial infarction in humans (a state in which at least 14 days have elapsed since the onset of myocardial infarction in rats), and the structural abnormality or function of the heart It refers to things with disabilities. Old myocardial infarction is associated with ischemic cardiomyopathy, which is accompanied by cardiac enlargement and impaired cardiac contractility. In the present application, the term “old myocardial infarction” is used interchangeably with “chronic myocardial infarction”.
- the HMGB1 fragment peptide of the present application suppresses cardiac structural abnormalities (eg, cardiac enlargement, cardiomyocyte hypertrophy and myocardial fibrosis) and functional disorders (eg, contractile dysfunction) in old myocardial infarction.
- cardiac structural abnormalities eg, cardiac enlargement, cardiomyocyte hypertrophy and myocardial fibrosis
- functional disorders eg, contractile dysfunction
- the HMGB1 fragment peptide of the present application exhibits an effect of improving cardiac function (for example, contractility) in cardiomyopathy. Therefore, it is considered that the HMGB1 fragment peptide of the present application exerts a wide therapeutic effect on heart diseases associated with cardiac structural abnormalities and / or functional disorders such as old myocardial infarction and cardiomyopathy.
- the present application also provides a pharmaceutical composition for preventing and / or treating chronic heart failure caused by cardiomyopathy, comprising an HMGB1 fragment peptide comprising the amino acid sequence set forth in SEQ ID NO: 1.
- Cardiomyopathy leads to a state of chronic heart failure when the cardiac function decreases as the disease progresses. Since HMGB1 fragment peptide can suppress cardiac structural abnormalities such as cardiac enlargement, cardiomyocyte hypertrophy, myocardial fibrosis and improve cardiac function in cardiomyopathy, it prevents and / or prevents chronic heart failure in patients with cardiomyopathy Can be treated.
- the present application also provides a pharmaceutical composition for preventing and / or treating chronic heart failure caused by old myocardial infarction, comprising an HMGB1 fragment peptide comprising the amino acid sequence set forth in SEQ ID NO: 1.
- Old cardiac myocardial infarction leads to a state of chronic heart failure when cardiac function is reduced due to progression of structural abnormalities of the heart.
- HMGB1 fragment peptide suppresses cardiac structural abnormalities such as cardiac enlargement, myocardial cell hypertrophy, and myocardial fibrosis in old myocardial infarction and improves cardiac function. Heart failure can be prevented and / or treated.
- chronic heart failure refers to a condition in which the heart's pumping function is reduced due to chronic myocardial injury, and the amount of blood that can meet the oxygen demand of the peripheral major organs cannot be pumped absolutely or relatively. It refers to a condition in which congestion has occurred in the lungs, systemic venous system, or both systems, causing problems in daily life.
- Types of chronic heart failure include heart failure with reduced left ventricular ejection fraction (heart failure with reduced ejection fraction: HFrEF) and heart failure with retained left ventricular ejection fraction (heart failure with preserved ejection fraction: HFpEF).
- HFrEF is characterized by a left ventricular ejection fraction of less than 50% and has impaired contractility.
- HFpEF is characterized by a left ventricular ejection fraction of 50% or more and has diastolic dysfunction.
- the HFrEF is due to dilated cardiomyopathy or ischemic cardiomyopathy.
- the HFpEF is due to hypertensive cardiomyopathy.
- the present application is selected from the group consisting of cardiac enlargement, cardiomyocyte hypertrophy and myocardial fibrosis in a patient with cardiomyopathy and old myocardial infarction containing an HMGB1 fragment peptide comprising the amino acid sequence set forth in SEQ ID NO: 1.
- a pharmaceutical composition for suppressing cardiac structural abnormalities is provided.
- the pharmaceutical composition of the present application suppresses a cardiac structural abnormality selected from the group consisting of (i) cardiac enlargement, cardiomyocyte hypertrophy and myocardial fibrosis in patients with cardiomyopathy and old myocardial infarction. In order to (ii) promote angiogenesis in the heart, or (iii) improve the contractility or dilatability of the heart.
- Examples of the contractility of the heart include, but are not limited to, the contractility of the ventricle, for example, the contractility of the left ventricle.
- Examples of the dilatability of the heart include, but are not limited to, ventricular dilatability, for example, left ventricular dilatability.
- the HMGB1 fragment peptide containing the amino acid sequence shown in SEQ ID NO: 1 means a peptide comprising a part of the HMGB1 protein and containing the amino acid sequence shown in SEQ ID NO: 1.
- Such a peptide can be obtained as a recombinant by incorporating DNA encoding the peptide into an appropriate expression system, or can be artificially synthesized.
- examples of the HMGB1 protein include, but are not limited to, a protein containing the amino acid sequence shown in SEQ ID NO: 2 and a protein encoded by DNA containing the base sequence shown in SEQ ID NO: 3. It is not a thing.
- HMGB1 fragment peptide containing the amino acid sequence set forth in SEQ ID NO: 1 in the present application include, but are not limited to, the following: 1) an HMGB1 fragment peptide comprising the amino acid sequence set forth in SEQ ID NO: 1 and having an activity of stimulating cell migration; 2) an HMGB1 fragment peptide comprising the amino acid sequence set forth in SEQ ID NO: 1 and having an activity of stimulating the migration of mesenchymal stem cells; 3) An HMGB1 fragment peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1.
- examples of cells whose migration is stimulated by the HMGB1 fragment peptide include, but are not limited to, bone marrow cells or bone marrow-derived cells (for example, bone marrow stem cells or bone marrow-derived stem cells).
- bone marrow cell means a cell existing in the bone marrow
- bone marrow-derived cell means “bone marrow cell” mobilized from the bone marrow to the outside of the bone marrow.
- bone marrow cells can also include undifferentiated cells such as stem cells and progenitor cells present in the bone marrow.
- examples of cells whose migration is stimulated by the HMGB1 fragment peptide include, but are not limited to, mesenchymal stem cells.
- mesenchymal stem cells are collected from bone marrow or other tissues (blood such as umbilical cord blood and skin, fat, dental pulp, etc.) and can be cultured and proliferated as adherent cells on culture dishes (plastic or glass). It is a cell having the ability to differentiate into mesenchymal tissues such as bone, cartilage, fat, and muscle. In one embodiment, the mesenchymal stem cell also has an ability to differentiate into epithelial tissue or neural tissue.
- Mesenchymal stem cells in the present application may exist as a heterogeneous cell population including not only stem cells in the narrow sense but also progenitor cells, and differentiated cells in addition to stem cells and / or progenitor cells in the narrow sense under culture conditions May also be included.
- the mesenchymal stem cells may be composed only of narrowly defined stem cells, or may be a cell population composed of a plurality of types of progenitor cells.
- a progenitor cell is defined as a cell having a unidirectional differentiation ability into a specific tissue cell other than the blood system, and a differentiation ability into a mesenchymal tissue, epithelial tissue, nerve tissue, parenchymal organ, or vascular endothelium.
- a cell having a unidirectional differentiation ability into a specific tissue cell other than the blood system and a differentiation ability into a mesenchymal tissue, epithelial tissue, nerve tissue, parenchymal organ, or vascular endothelium.
- cells whose migration is stimulated by the HMGB1 fragment peptide include, but are not limited to, bone marrow mesenchymal stem cells and bone marrow-derived mesenchymal stem cells.
- bone marrow mesenchymal stem cells are cells that are present in the bone marrow, can be collected from the bone marrow, and cultured and proliferated as adherent cells on a culture dish (plastic or glass). Bone, cartilage, fat It is a cell having a characteristic of differentiating into mesenchymal tissue such as muscle, nerve tissue and epithelial tissue.
- bone marrow mesenchymal stem cell is used interchangeably with “bone marrow mesenchymal stromal cell”, “bone marrow pluripotent stem cell” and “bone marrow pluripotent stromal cell”.
- Bone marrow-derived mesenchymal stem cells refers to bone marrow mesenchymal stem cells mobilized from the bone marrow to the outside of the bone marrow. Peripheral blood sampling, as well as mesenchymal tissue such as fat, epithelial tissue such as skin, brain It is a cell that can be obtained by collecting from nerve tissue.
- the term “bone marrow-derived mesenchymal stem cell” is used interchangeably with “bone marrow-derived mesenchymal stromal cell”, “bone marrow-derived pluripotent stem cell”, and “bone marrow-derived pluripotent stromal cell”. It is done.
- bone marrow mesenchymal stem cells and bone marrow-derived mesenchymal stem cells can be used directly after collection or by administering cells once attached to a culture dish to an injured part of a living body, for example, epithelial systems such as keratinocytes constituting the skin. It also has the feature of having the ability to differentiate into tissues of the nervous system that constitute the tissue and brain.
- Bone marrow mesenchymal stem cells and bone marrow-derived mesenchymal stem cells are osteoblasts (can be identified by the presence of calcium deposition when differentiation is induced), chondrocytes (positive for Alcian blue staining, safranin-O staining, etc.)
- chondrocytes positive for Alcian blue staining, safranin-O staining, etc.
- mesenchymal cells such as fibroblasts, smooth muscle cells, skeletal muscle cells, stromal cells, tendon cells, nerve cells, pigment cells , Epidermal cells, hair follicle cells (expressing cytokeratin family, hair keratin family, etc.), epithelial cells (eg, epidermal keratinocytes, intestinal epithelial cells express cytokeratin family, etc.), endothelial cells, further liver, It is preferable to have the ability to differentiate into parenchymal organ cells such as kidney and pancreas, but the differentiate
- Mouse mesenchymal stem cell markers include CD44 positive, PDGFR ⁇ positive, PDGFR ⁇ positive, CD45 negative, Lin negative, Sca-1 positive, c-kit negative, CD90 positive, CD105 positive, CD29 positive, Flk-1 negative, CD271 Although all or part of positive and CD11b negative can be illustrated, it is not limited to these.
- rat mesenchymal stem cell markers include PDGFR ⁇ -positive, CD44-positive, CD54-positive, CD73-positive, CD90-positive, CD105-positive, CD29-positive, CD271-positive, CD31-negative, and CD45-negative all or part of them. It is not limited to.
- examples of cells whose migration is stimulated by the HMGB1 fragment peptide include, but are not limited to, PDGFR ⁇ -positive cells.
- PDGFR ⁇ -positive cells whose migration is stimulated by the HMGB1 fragment peptide include PDGFR ⁇ -positive mesenchymal stem cells, PDGFR ⁇ -positive bone marrow-derived mesenchymal stem cells, PDGFR ⁇ -positive bone marrow-derived cells, and bone marrow collection (bone marrow cell collection)
- cells obtained as adherent cells by mononuclear cell fractionation in blood obtained by peripheral blood collection can be exemplified, but the present invention is not limited thereto.
- PDGFR ⁇ -positive mesenchymal stem cells examples include cells that are positive for PDGFR ⁇ and CD44, cells that are positive for PDGFR ⁇ and CD90, cells that are positive for PDGFR ⁇ and CD105, cells that are positive for PDGFR ⁇ and CD29, etc. It is done.
- the PDGFR ⁇ -positive mesenchymal stem cell may be a CD44-negative cell.
- one or more amino acid residues in the amino acid sequence described in SEQ ID NO: 1 are modified in place of or together with the HMGB1 fragment peptide containing the amino acid sequence described in SEQ ID NO: 1 (
- a peptide having an amino acid sequence that is substituted, deleted, inserted or added) and having an activity of stimulating cell migration can also be used.
- Examples of such peptides include but are not limited to the following: i) One or more (for example, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 in the amino acid sequence shown in SEQ ID NO: 1 An amino acid sequence in which 5 to 1, 1 to 4, 1 to 3, or 1 or 2 amino acids are substituted, deleted, inserted, or added, and stimulates cell migration A peptide having ii) One or more (for example, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, or 1 in the amino acid sequence shown in SEQ ID NO: 1.
- the cells whose migration is stimulated by these peptides include mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, PDGFR ⁇ -positive cells, PDGFR ⁇ -positive mesenchymal stem cells, PDGFR ⁇ -positive bone marrow-derived mesenchymal stem cells, and Examples include PDGFR ⁇ -positive bone marrow-derived cells that can be obtained as adherent cells by mononuclear cell culture in blood obtained by bone marrow collection (bone marrow cell collection) or peripheral blood collection. Is not to be done.
- a peptide or the like An effective amount of the peptide of the present application and a pharmaceutical composition containing the peptide (hereinafter referred to as a peptide or the like) is administered to a subject for the treatment or prevention of the diseases and symptoms described herein.
- an effective amount refers to an amount sufficient for the treatment or prevention of the diseases and symptoms described herein.
- Treatment in the present application includes, but is not limited to, reduction, delay, prevention, improvement, remission, cure, complete cure and the like. Further, prevention in the present application includes, but is not limited to, reduction, delay, prevention, and the like.
- the target in the present application is not particularly limited, and examples include mammals, birds and fish.
- mammals include humans or non-human animals, and examples include, but are not limited to, humans, mice, rats, monkeys, pigs, dogs, rabbits, hamsters, guinea pigs, horses, sheep, and whales. is not.
- the term “subject” is used interchangeably with “patient”, “individual” and “animal”.
- the administration site of the peptide or the like of the present application a site having a structural or functional abnormality of the tissue or the vicinity thereof, a site different from them (other site), a site having a structural or functional abnormality of the tissue Any site away from the site, distal to the site with a structural or functional abnormality of the tissue, or distal and ectopic to a site with a structural or functional abnormality of the tissue Even when administered to a site, the peptide of the present application can exert its effect.
- a site having a structural or functional abnormality of the heart by administering the peptide of the present application at or near a site having a structural or functional abnormality of the heart, cells (eg, mesenchymal stem cells) are mobilized at the administration site, and regeneration of heart tissue or cardiac Improvement of structural or functional abnormalities is induced or promoted.
- the bone marrow is moved to or near the site having a structural or functional abnormality of the heart.
- Bone marrow cells eg, bone marrow mesenchymal stem cells
- peripheral circulation is also referred to as “blood circulation” and “peripheral circulation blood flow”.
- the peptide of the present application can be applied to any tissue such as a tissue different from the heart tissue, a tissue distant from the heart tissue, a tissue distal to the heart tissue, or a tissue distal and ectopic to the heart tissue. Even if administered, the effect can be exerted. That is, the peptide of the present application is effectively used for regenerating heart tissue in which it is difficult to administer a drug directly from outside the body, or for improving a structural or functional abnormality of the heart.
- Examples of the administration method of the peptide of the present application include oral administration and parenteral administration.
- Examples of the parenteral administration method include intravascular administration (intraarterial administration, intravenous administration, etc.), intramuscular administration, subcutaneous administration, and intradermal administration. Administration, intraperitoneal administration, nasal administration, pulmonary administration, transdermal administration, and the like, but are not limited thereto.
- the peptide of the present application can be administered systemically or locally (for example, subcutaneously, intradermally, skin surface, eyeball or eyelid conjunctiva, nasal cavity) by injection administration such as intravenous injection, intramuscular injection, intraperitoneal injection, subcutaneous injection, etc. Mucosa, oral cavity and gastrointestinal mucosa, vaginal / intrauterine mucosa, or damaged site).
- a cell that secretes the peptide of the present application a gene therapy vector into which a DNA encoding the peptide is inserted, and a pharmaceutical composition containing them can also be used.
- the administration method can be appropriately selected depending on the age and symptoms of the patient.
- the dose can be selected in the range of 0.0000001 mg to 1000 mg per kg of body weight per administration.
- the dose can be selected within the range of 0.00001 to 100,000 mg / body per patient.
- the peptide can be administered so that the amount falls within the above range.
- the pharmaceutical composition in the present application is not limited to these doses.
- the pharmaceutical composition of the present application can be formulated according to a conventional method (for example, Remington's Pharmaceutical, Science, Latest Edition, Mark, Publishing Company, Easton, USA) and includes a pharmaceutically acceptable carrier or additive.
- a pharmaceutically acceptable carrier or additive There may be.
- surfactants, excipients, coloring agents, flavoring agents, preservatives, stabilizers, buffering agents, suspending agents, tonicity agents, binders, disintegrating agents, lubricants, fluidity promoters, flavoring agents can be used as appropriate.
- J2N-k hamster (18 weeks old, male, 20 animals in total), which is a model animal of dilated cardiomyopathy, was obtained from Japan SLC and used for experiments after acclimation for 2 weeks. J2N-k hamsters spontaneously develop dilated cardiomyopathy due to a deletion mutation in the ⁇ -sarcoglycan gene (specifically, cardiomyocyte shedding and fibrosis began around 5 weeks of age, approximately 20 weeks Shows heart expansion and cardiac dysfunction at age, eventually dies of congestive heart failure in about 1 year, J Biochem. 2003 Aug; 134 (2): 269-76).
- HMGB1 peptide 1-44
- 1-44 1-44
- the test substance was administered once a day in an amount of 3 ml / kg of HMGB1 peptide (1-44) solution adjusted to a concentration of 1 mg / ml using PBS as a solvent (3 mg / kg as the peptide dose). It was performed by injecting into the external jugular vein for consecutive days.
- PBS was injected into the external jugular vein once a day for 4 consecutive days in an amount of 3 ml / kg.
- thoracotomy was performed under deep anesthesia, and the heart was removed.
- the heart was examined for histopathology by dividing the mid-portion for cryopreservation and paraffin fixation.
- a molecular biological study was performed using the myocardium at the apex to evaluate the effect of administration of HMGB1 peptide (1-44).
- RT-PCR Using myocardium at the apex, the expression of VEGF, an angiogenic factor secreted by mesenchymal bone marrow stem cells, and TSG-6, an anti-inflammatory cytokine, were evaluated by RT-PCR. vii) Mitochondrial structure The structure of cardiomyocytes was observed with an electron microscope.
- HMGB1 peptide (1-44) As a result of immunostaining, the number of blood vessels in the HMGB1 peptide (1-44) group was significantly higher than that in the PBS group in the mid layer, and angiogenesis was enhanced (FIG. 3). ). Also in the subendocardial layer, the HMGB1 peptide (1-44) group tended to have more blood vessels than the PBS group. iv) Cardiomyocyte hypertrophy As a result of PAS staining, the HMGB1 peptide (1-44) group has a significantly smaller minor axis than the PBS group in both the subendocardial layer and the mid layer, and cardiomyocyte hypertrophy Was suppressed (FIG. 4).
- the test substance was administered once a day in an amount of 3 ml / kg of HMGB1 peptide (1-44) solution adjusted to a concentration of 1 mg / ml using PBS as a solvent (3 mg / kg as the peptide dose). It was performed by injecting into the femoral vein for consecutive days.
- PBS was injected into the femoral vein once a day for 4 consecutive days in an amount of 3 ml / kg.
- resuscitation was performed under deep anesthesia, and the heart was removed.
- puncture was performed from the right atrium toward the inferior vena cava to collect 5 ml or more of blood, and the heart was divided into four short-axis slices of equal thickness and divided for cryopreservation and paraffin fixation. . Both groups were compared using cardiac physiology, histopathology, and molecular biology techniques to evaluate the effects of HMGB1 peptide (1-44) administration.
- a state in which two weeks (14 days) have elapsed since the onset of myocardial infarction in a model rat corresponds to a state in which at least 30 days have elapsed since the onset of myocardial infarction in humans.
- the old-model myocardial infarction model rat created this time had LVEF decreased to 42% at the time before medication, and the progression of cardiac expansion was seen in the control group. It can be regarded as a model.
- v) Mesenchymal stem cell mobilization at the infarct boundary As a result of immunostaining of myocardial tissue, cells positive for both PDGFR ⁇ and CD90 and cells positive for both PDGFR ⁇ and CD105 are HMGB1 peptide (1-44) group It was observed that the area was mobilized in the vicinity of the infarct boundary (FIGS. 17 and 18). Furthermore, more PDGFR ⁇ -positive and CD90-positive cells were present in the vicinity of the infarct boundary of the HMGB1 peptide (1-44) group than in the PBS group (FIG. 19).
- the DIS / Eis rat is a model that develops hypertension when fed on a high salt diet and develops heart failure at a high rate (for example, when fed with 8% NaCl supplemented diet from 6 weeks of age, blood pressure reaches 250 mmHg at 9 weeks of age. Deaths began to appear at 12 weeks of age, and it has been confirmed that deaths occur at a high rate by 16 weeks after birth).
- 8% NaCl supplemented feed and 0.3% NaCl supplemented feed were continued until 15 weeks of age. Except for meals, there were no obstacles to free exercise, and the cages were kept clean and resting without restrictions such as drinking and eating.
- the test substance was administered once a day in an amount of 3 ml / kg of HMGB1 peptide (1-44) solution adjusted to a concentration of 1 mg / ml using PBS as a solvent (3 mg / kg as the peptide dose).
- the HMGB1 peptide (1-44) administration group fed with a high salt diet is referred to as ⁇ High-1-44 group ''
- the control group fed with a high salt diet is referred to as ⁇ High-PBS group ''
- the low salt diet group is referred to as ⁇ It is abbreviated as “Low-PBS group”.
- the LVAWd of the High-PBS group and the High-1-44 group was larger than that of the Low-PBS group, but the LVAWd of the High-1-44 group was smaller than that of the High-PBS group, and the HMGB1 peptide (1- There was a tendency that the increase in the left ventricular anterior wall thickness was suppressed by the administration of 44).
- Myocardial fibrosis The results of Sirius red staining of myocardial tissue sections are shown in FIG. Compared with the Low-PBS group, increased fibrosis around the coronary artery was observed in the High-PBS group.
- fibrosis rate the proportion of Sirius red staining positive area in the whole heart (fibrosis rate) is smaller in the High-1-44 group than in the High-PBS group, and fibrosis of the myocardium by administration of HMGB1 peptide (1-44) The tendency which is suppressed was seen (FIG. 23A). Fibrosis rate in the left ventricle was smaller in the High-1-44 group than in the High-PBS group, indicating that administration of HMGB1 peptide (1-44) suppressed myocardial fibrosis (Fig. 23B).
- DIS / Eis rats fed a high salt diet develop hypertension. It was also confirmed that the rat actually developed cardiac hypertrophy and cardiomyocyte hypertrophy. Therefore, the DIS / Eis rat fed with a high salt diet used in this example can be evaluated as a model of hypertensive cardiomyopathy. Cardiac hypertrophy / cardiomyocyte hypertrophy is a structural abnormality that causes a reduction in the ability of the heart to expand. The DIS / Eis rat fed with a high salt diet used in this example was able to be evaluated as a model of HFpEF because it maintained normal left ventricular contractility and produced cardiac hypertrophy / cardiomyocyte hypertrophy.
- HMGB1 peptide (1-44) of the present invention suppresses cardiac hypertrophy and cardiomyocyte hypertrophy in DIS / Eis rats fed with high salt diet, it can be used for the prevention and / or treatment of hypertensive cardiomyopathy and HFpEF. Is possible.
- the pharmaceutical composition containing the peptide of the present application is useful as a pharmaceutical composition for the prevention and / or treatment of heart disease accompanied by cardiac structural abnormality and / or functional disorder.
- the pharmaceutical composition containing the peptide of the present application is a patient with cardiomyopathy and old myocardial infarction and chronic heart failure caused by these, and patients who are difficult to operate due to factors such as old age, or existing chronic heart failure treatment It is expected to bring great benefits to patients for whom the drug is not effective enough.
- the pharmaceutical composition containing the peptide of the present application exhibits effects such as cardiac function improvement and suppression of cardiomyocyte hypertrophy in a plurality of cardiomyopathy models such as dilated cardiomyopathy, ischemic cardiomyopathy and hypertensive cardiomyopathy, A wide range of therapeutic effects can be expected for various cardiomyopathy, including idiopathic and secondary.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
〔1〕
以下の(a)から(c)のいずれかに記載の物質(以下、物質Aと称する)を含有する、心臓の構造異常および/または機能障害を伴う心疾患の予防および/または治療のための医薬組成物:
(a)配列番号:1に記載のアミノ酸配列を含むHMGB1断片ペプチド;
(b)配列番号:1に記載のアミノ酸配列において1若しくは複数個のアミノ酸が置換、欠失、挿入若しくは付加されたアミノ酸配列を含み、且つ、細胞の遊走を刺激する活性を有するペプチド; および
(c)配列番号:1に記載のアミノ酸配列と約80%以上の配列同一性を有するアミノ酸配列を含み、且つ、細胞の遊走を刺激する活性を有するペプチド。
〔2〕
心臓の構造異常および/または機能障害を伴う心疾患が、心筋症である、〔1〕に記載の医薬組成物。
〔3〕
心筋症が、特発性心筋症である、〔2〕に記載の医薬組成物。
〔4〕
特発性心筋症が、拡張型心筋症、肥大型心筋症、拘束型心筋症および不整脈原性右室心筋症からなる群より選択される、〔3〕に記載の医薬組成物。
〔5〕
心筋症が、二次性心筋症である、〔2〕に記載の医薬組成物。
〔6〕
二次性心筋症が、虚血性心筋症、高血圧性心筋症、弁膜症性心筋症、薬剤誘発性心筋症、アルコール性心筋症、ミトコンドリア心筋症、心サルコイドーシスに起因する心筋症、心アミロイドーシスに起因する心筋症、心筋炎に起因する心筋症、筋ジストロフィーに起因する心筋症、心ファブリー病に起因する心筋症、および周産期心筋症からなる群より選択される、〔5〕に記載の医薬組成物。
〔7〕
心臓の構造異常および/または機能障害を伴う心疾患が、陳旧性心筋梗塞である、〔1〕に記載の医薬組成物。
〔8〕
物質Aを含有する、心筋症または陳旧性心筋梗塞に起因する慢性心不全の予防および/または治療のための医薬組成物。
〔9〕
物質Aを含有する、心筋症または陳旧性心筋梗塞の患者において心拡大、心筋細胞肥大および心筋線維化からなる群より選択される心臓の構造異常を抑制するための医薬組成物。
〔10〕
物質Aを含有する、拡張型心筋症、虚血性心筋症および高血圧性心筋症からなる群より選択される心筋症の予防および/または治療のための医薬組成物。
〔11〕
虚血性心筋症が、陳旧性心筋梗塞に起因するものである、〔10〕に記載の医薬組成物。
〔12〕
物質Aを含有する、拡張型心筋症、虚血性心筋症および高血圧性心筋症からなる群より選択される心筋症に起因する慢性心不全の予防および/または治療のための医薬組成物。
〔13〕
虚血性心筋症が、陳旧性心筋梗塞に起因するものである、〔12〕に記載の医薬組成物。
〔14〕
慢性心不全が、拡張型心筋症または虚血性心筋症に起因するものである、〔12〕に記載の医薬組成物。
〔15〕
拡張型心筋症または虚血性心筋症に起因する慢性心不全が、HFrEFである、〔14〕に記載の医薬組成物。
〔16〕
慢性心不全が、高血圧性心筋症に起因するものである、〔12〕に記載の医薬組成物。
〔17〕
高血圧性心筋症に起因する慢性心不全が、HFpEFである、〔16〕に記載の医薬組成物。
〔A1〕
物質Aの有効量を対象に投与する工程を含む、心臓の構造異常および/または機能障害を伴う心疾患を予防および/または治療する方法。
〔A2〕
心臓の構造異常および/または機能障害を伴う心疾患が、心筋症である、〔A1〕に記載の方法。
〔A3〕
心筋症が、特発性心筋症である、〔A2〕に記載の方法。
〔A4〕
特発性心筋症が、拡張型心筋症、肥大型心筋症、拘束型心筋症および不整脈原性右室心筋症からなる群より選択される、〔A3〕に記載の方法。
〔A5〕
心筋症が、二次性心筋症である、〔A2〕に記載の方法。
〔A6〕
二次性心筋症が、虚血性心筋症、高血圧性心筋症、弁膜症性心筋症、薬剤誘発性心筋症、アルコール性心筋症、ミトコンドリア心筋症、心サルコイドーシスに起因する心筋症、心アミロイドーシスに起因する心筋症、心筋炎に起因する心筋症、筋ジストロフィーに起因する心筋症、心ファブリー病に起因する心筋症、および周産期心筋症からなる群より選択される、〔A5〕に記載の方法。
〔A7〕
心臓の構造異常および/または機能障害を伴う心疾患が、陳旧性心筋梗塞である、〔A1〕に記載の方法。
〔A8〕
物質Aの有効量を対象に投与する工程を含む、心筋症または陳旧性心筋梗塞に起因する慢性心不全を予防および/または治療する方法。
〔A9〕
物質Aの有効量を対象に投与する工程を含む、心筋症または陳旧性心筋梗塞の患者において心拡大、心筋細胞肥大および心筋線維化からなる群より選択される心臓の構造異常を抑制する方法。
〔A10〕
物質Aの有効量を対象に投与する工程を含む、拡張型心筋症、虚血性心筋症および高血圧性心筋症からなる群より選択される心筋症を予防および/または治療する方法。
〔A11〕
虚血性心筋症が、陳旧性心筋梗塞に起因するものである、〔A10〕に記載の方法。
〔A12〕
物質Aの有効量を対象に投与する工程を含む、拡張型心筋症、虚血性心筋症および高血圧性心筋症からなる群より選択される心筋症に起因する慢性心不全を予防および/または治療する方法。
〔A13〕
虚血性心筋症が、陳旧性心筋梗塞に起因するものである、〔A12〕に記載の方法。
〔A14〕
慢性心不全が、拡張型心筋症または虚血性心筋症に起因するものである、〔A12〕に記載の方法。
〔A15〕
拡張型心筋症または虚血性心筋症に起因する慢性心不全が、HFrEFである、〔A14〕に記載の方法。
〔A16〕
慢性心不全が、高血圧性心筋症に起因するものである、〔A12〕に記載の方法。
〔A17〕
高血圧性心筋症に起因する慢性心不全が、HFpEFである、〔A16〕に記載の方法。
〔B1〕
心臓の構造異常および/または機能障害を伴う心疾患の予防および/または治療に用いるための、物質A。
〔B2〕
心臓の構造異常および/または機能障害を伴う心疾患が、心筋症である、〔B1〕に記載の物質A。
〔B3〕
心筋症が、特発性心筋症である、〔B2〕に記載の物質A。
〔B4〕
特発性心筋症が、拡張型心筋症、肥大型心筋症、拘束型心筋症および不整脈原性右室心筋症からなる群より選択される、〔B3〕に記載の物質A。
〔B5〕
心筋症が、二次性心筋症である、〔B2〕に記載の物質A。
〔B6〕
二次性心筋症が、虚血性心筋症、高血圧性心筋症、弁膜症性心筋症、薬剤誘発性心筋症、アルコール性心筋症、ミトコンドリア心筋症、心サルコイドーシスに起因する心筋症、心アミロイドーシスに起因する心筋症、心筋炎に起因する心筋症、筋ジストロフィーに起因する心筋症、心ファブリー病に起因する心筋症、および周産期心筋症からなる群より選択される、〔B5〕に記載の物質A。
〔B7〕
心臓の構造異常および/または機能障害を伴う心疾患が、陳旧性心筋梗塞である、〔B1〕に記載の物質A。
〔B8〕
心筋症または陳旧性心筋梗塞に起因する慢性心不全の予防および/または治療に用いるための、物質A。
〔B9〕
心筋症または陳旧性心筋梗塞の患者において心拡大、心筋細胞肥大および心筋線維化からなる群より選択される心臓の構造異常の抑制に用いるための、物質A。
〔B10〕
拡張型心筋症、虚血性心筋症および高血圧性心筋症からなる群より選択される心筋症の予防および/または治療に用いるための、物質A。
〔B11〕
虚血性心筋症が、陳旧性心筋梗塞に起因するものである、〔B10〕に記載の物質A。
〔B12〕
拡張型心筋症、虚血性心筋症および高血圧性心筋症からなる群より選択される心筋症に起因する慢性心不全の予防および/または治療に用いるための、物質A。
〔B13〕
虚血性心筋症が、陳旧性心筋梗塞に起因するものである、〔B12〕に記載の物質A。
〔B14〕
慢性心不全が、拡張型心筋症または虚血性心筋症に起因するものである、〔B12〕に記載の物質A。
〔B15〕
拡張型心筋症または虚血性心筋症に起因する慢性心不全が、HFrEFである、〔B14〕に記載の物質A。
〔B16〕
慢性心不全が、高血圧性心筋症に起因するものである、〔B12〕に記載の物質A。
〔B17〕
高血圧性心筋症に起因する慢性心不全が、HFpEFである、〔B16〕に記載の物質A。
〔C1〕
心臓の構造異常および/または機能障害を伴う心疾患の予防および/または治療のための医薬の製造における、物質Aの使用。
〔C2〕
心臓の構造異常および/または機能障害を伴う心疾患が、心筋症である、〔C1〕に記載の使用。
〔C3〕
心筋症が、特発性心筋症である、〔C2〕に記載の使用。
〔C4〕
特発性心筋症が、拡張型心筋症、肥大型心筋症、拘束型心筋症および不整脈原性右室心筋症からなる群より選択される、〔C3〕に記載の使用。
〔C5〕
心筋症が、二次性心筋症である、〔C2〕に記載の使用。
〔C6〕
二次性心筋症が、虚血性心筋症、高血圧性心筋症、弁膜症性心筋症、薬剤誘発性心筋症、アルコール性心筋症、ミトコンドリア心筋症、心サルコイドーシスに起因する心筋症、心アミロイドーシスに起因する心筋症、心筋炎に起因する心筋症、筋ジストロフィーに起因する心筋症、心ファブリー病に起因する心筋症、および周産期心筋症からなる群より選択される、〔C5〕に記載の使用。
〔C7〕
心臓の構造異常および/または機能障害を伴う心疾患が、陳旧性心筋梗塞である、〔C1〕に記載の使用。
〔C8〕
心筋症または陳旧性心筋梗塞に起因する慢性心不全の予防および/または治療のための医薬の製造における、物質Aの使用。
〔C9〕
心筋症または陳旧性心筋梗塞の患者において心拡大、心筋細胞肥大および心筋線維化からなる群より選択される心臓の構造異常を抑制するための医薬の製造における、物質Aの使用。
〔C10〕
拡張型心筋症、虚血性心筋症および高血圧性心筋症からなる群より選択される心筋症の予防および/または治療のための医薬の製造における、物質Aの使用。
〔C11〕
虚血性心筋症が、陳旧性心筋梗塞に起因するものである、〔C10〕に記載の使用。
〔C12〕
拡張型心筋症、虚血性心筋症および高血圧性心筋症からなる群より選択される心筋症に起因する慢性心不全の予防および/または治療のための医薬の製造における、物質Aの使用。
〔C13〕
虚血性心筋症が、陳旧性心筋梗塞に起因するものである、〔C12〕に記載の使用。
〔C14〕
慢性心不全が、拡張型心筋症または虚血性心筋症に起因するものである、〔C12〕に記載の使用。
〔C15〕
拡張型心筋症または虚血性心筋症に起因する慢性心不全が、HFrEFである、〔C14〕に記載の使用。
〔C16〕
慢性心不全が、高血圧性心筋症に起因するものである、〔C12〕に記載の使用。
〔C17〕
高血圧性心筋症に起因する慢性心不全が、HFpEFである、〔C16〕に記載の使用。
1) 配列番号:1に記載のアミノ酸配列を含み、且つ、細胞の遊走を刺激する活性を有するHMGB1断片ペプチド;
2) 配列番号:1に記載のアミノ酸配列を含み、且つ、間葉系幹細胞の遊走を刺激する活性を有するHMGB1断片ペプチド;
3) 配列番号:1に記載のアミノ酸配列からなるHMGB1断片ペプチド。
i) 配列番号:1に記載のアミノ酸配列において1若しくは複数個(例えば1個~10個、1個~9個、1個~8個、1個~7個、1個~6個、1個~5個、1個~4個、1個~3個、または1個若しくは2個)のアミノ酸が置換、欠失、挿入若しくは付加されたアミノ酸配列を含み、且つ、細胞の遊走を刺激する活性を有するペプチド;
ii) 配列番号:1に記載のアミノ酸配列において1若しくは複数個(例えば1個~10個、1個~9個、1個~8個、1個~7個、1個~6個、1個~5個、1個~4個、1個~3個、または1個若しくは2個)のアミノ酸が置換、欠失、挿入若しくは付加されたアミノ酸配列からなり、且つ、細胞の遊走を刺激する活性を有するペプチド;
iii) 配列番号:1に記載のアミノ酸配列と約80%以上、例えば約85%以上、約90%以上、約91%以上、約92%以上、約93%以上、約94%以上、約95%以上、約96%以上、約97%以上、約98%以上または約99%以上の配列同一性を有するアミノ酸配列を含み、且つ、細胞の遊走を刺激する活性を有するペプチド;
iv) 配列番号:1に記載のアミノ酸配列と約80%以上、例えば約85%以上、約90%以上、約91%以上、約92%以上、約93%以上、約94%以上、約95%以上、約96%以上、約97%以上、約98%以上または約99%以上の配列同一性を有するアミノ酸配列からなり、且つ、細胞の遊走を刺激する活性を有するペプチド。
また、これらのペプチドにより遊走が刺激される細胞としては、間葉系幹細胞、骨髄由来間葉系幹細胞、PDGFRα陽性細胞、PDGFRα陽性の間葉系幹細胞、PDGFRα陽性の骨髄由来間葉系幹細胞、およびPDGFRα陽性の骨髄由来細胞であって骨髄採取(骨髄細胞採取)または末梢血採血により得られた血液中の単核球分画細胞培養により付着細胞として得られる細胞などが例示できるが、これらに制限されるものではない。
拡張型心筋症に対するHMGB1断片ペプチドの有効性の評価
拡張型心筋症モデル動物であるJ2N-kハムスター(18週齢、オス、計20匹)を日本SLCより入手し、2週間馴化した後、実験に用いた。J2N-kハムスターは、δ-サルコグリカン遺伝子の欠失変異が原因で拡張型心筋症を自然発症する(具体的には、5週齢前後で心筋細胞の脱落と線維化が始まり、約20週齢で心拡大および心機能障害を示し、最終的に約1年でうっ血性心不全により死亡する。J Biochem. 2003 Aug;134(2):269-76)。また、ヒト由来のHMGB1タンパク質のアミノ酸残基1-44(配列番号:1)からなるペプチドを固相法により化学合成した。以下、当該ペプチドをHMGB1ペプチド(1-44)と称し、実施例に対応する図面においては「1-44」と省略して表記する。
i)心機能
投薬前、投薬後4週間目および6週間目に心エコーを実施し、左室拡張末期径(LVDd)、左室収縮末期径(LVDs)および左室駆出率(LVEF)を測定、算出して心機能評価を行った。
ii)心筋の線維化
心筋組織切片をシリウスレッドで染色し、心筋全体の面積に占める染色陽性領域の割合を線維化率(%)として算出した。
iii)血管新生
抗CD31抗体を用いて心筋組織切片の免疫染色を行い、血管数(血管内皮細胞数)を測定した。この測定を異なる5視野で実施し、平均値を算出した。
iv)心筋細胞の肥大
心筋組織切片のPAS(Periodic Acid Schiff)染色を行い、核構造を保持している心筋細胞の短径を測定し、平均化した。この測定を異なる5視野で実施し、平均値を算出した。
v)間葉系幹細胞の動員
間葉系幹細胞の表面マーカーであるPDGFRαおよびCD29に対する抗体を用いて心筋組織切片の免疫染色を行い、間葉系幹細胞の集積が認められるかを評価した。細胞核の染色はDAPIを用いて行った。
vi) RT-PCR
心尖部の心筋を用いて、間葉系骨髄幹細胞により分泌される血管新生因子であるVEGF、抗炎症サイトカインであるTSG-6の心筋内発現をRT-PCRにより評価した。
vii)ミトコンドリアの構造
心筋細胞の構造を電子顕微鏡で観察した。具体的には、mid-portionの全層心筋をサンプルとし、1/2カルノフスキーによる前固定、2%四酸化オスミウム酸による後固定、0.5%酢酸ウラン水溶液によるブロック染色、およびエタノールによる脱水の後、エポキシ樹脂(Quetol812)を浸透させて包埋・重合し、超薄切切片(70~110nm)を作製し、酢酸ウランおよび鉛染色液による電子染色を実施した上で、電子顕微鏡(H-7500、日立ハイテクノロジーズ)にて観察した。
i)心機能
投薬4週間後および6週間後の心機能評価では、PBS群と比較してHMGB1ペプチド(1-44)群でLVEFが有意に高値であり、左室収縮能の低下が抑制されていた(図1)。かかる結果は、HMGB1ペプチド(1-44)による心機能の改善効果を示すものである。LVDdおよびLVDsについては、投薬4週間後および6週間後いずれの時点においても有意差はなかった。
ii)心筋の線維化
解析の結果、シリウスレッド染色陽性領域の割合はPBS群よりもHMGB1ペプチド(1-44)群の方が有意に小さく、心筋の線維化が抑制されていることが示された(図2)。
iii)血管新生
免疫染色の結果、mid layerにおいて、HMGB1ペプチド(1-44)群の方がPBS群よりも有意に血管数が多く、血管新生が亢進していることが示された(図3)。subendocardial layerにおいても、HMGB1ペプチド(1-44)群の方がPBS群より血管数が多い傾向が見られた。
iv)心筋細胞の肥大
PAS染色の結果、subendocardial layerおよびmid layerいずれにおいても、HMGB1ペプチド(1-44)群の方がPBS群よりも有意に心筋細胞の短径が小さく、心筋細胞の肥大化が抑制されていることが示された(図4)。
v)間葉系幹細胞の動員
免疫染色の結果、PDGFRαおよびCD29の両方が陽性である細胞がHMGB1ペプチド(1-44)群の心筋組織に動員されていることが認められた(図5)。また、HMGB1ペプチド(1-44)群の心筋組織には、PBS群よりも有意に多くのPDGFRα陽性かつCD29陽性の細胞が存在していた(図6)。
vi) RT-PCR
解析の結果、VEGFおよびTSG-6のいずれも、PBS群よりもHMGB1ペプチド(1-44)群において有意に発現量が高かった(図7)。
vii)ミトコンドリアの構造
心筋細胞を電子顕微鏡で観察した結果、PBS群においてはミトコンドリアのクリステ構造の消失が見られたが、HMGB1ペプチド(1-44)群ではクリステ構造が維持されていた(図8)。かかる結果は、HMGB1ペプチド(1-44)の投与による心機能維持効果を裏付けるものである。
拡張型心筋症に対するHMGB1断片ペプチドの有効性の評価(長期観察)
実施例1と同様にJ2N-kハムスターを20匹用意し、HMGB1ペプチド(1-44)投与群(n=11)およびPBS投与群(対照、n=9)に分け、20週齢目から投与を開始した。被験物質の投与は、PBSを溶媒として1mg/mlの濃度に調整したHMGB1ペプチド(1-44)溶液を3ml/kgの量(ペプチドの投与量としては3mg/kg)で1日1回、4日間連続で外頚静脈に注入することにより行った。対照群には、PBSを3ml/kgの量で1日1回、4日間連続で外頚静脈に注入した。その後は通常の条件で飼育しながら、心機能および生存率の評価を継続的に行った。
i)心機能
投薬前、投薬後4週間目、およびその後2週間ごとに心エコーを実施し、LVEFを計測した。
ii)生存率
最終投与後、通常の条件で飼育を継続して生存率を評価した。
i)心機能
HMGB1ペプチド(1-44)群のLVEFは、投与後6週まで、PBS群よりも有意に高い値を維持していた(図9)。
ii)生存率
長期観察の結果、HMGB1ペプチド(1-44)群において生存率が高い傾向が見られた(図10)。
陳旧性心筋梗塞後の心機能改善に関するHMGB1断片ペプチドの有効性の評価
SDラット(7週齢、オス、体重約250g)を吸入麻酔薬セボフレン(またはイソフルラン)で麻酔し、十分な抑制状態が得られた後に気管内挿管し吸入麻酔薬で深麻酔を維持した。仰臥位、左第4肋間で開胸し、冠動脈左前下行枝近位部を6-0 prolene縫合糸で結紮し、広範囲心筋梗塞モデルを作成した。梗塞作成から2週間後に心エコーで心機能評価を行い、広範囲梗塞が得られた症例(LVEF<50%)を陳旧性心筋梗塞モデルラットとした(計17匹)。また、上記実施例と同様に、配列番号:1からなるHMGB1ペプチド(1-44)を用いた。
i)心機能
投薬後1、2、および4週間目に心エコーを実施し、左室拡張末期径(LVDd)、左室収縮末期径(LVDs)および左室駆出率(LVEF)を測定、算出して心機能評価を行った。
ii)心筋の線維化
心筋組織切片をシリウスレッドで染色し、左室心筋全体の面積に占める染色陽性領域の割合を線維化率(%)として算出した。
iii)血管新生
梗塞境界部においてvon-Willbrand因子染色を行い、血管数(血管内皮細胞数)を測定した。この測定を異なる10視野で実施し、平均値を算出した。
iv)心筋細胞の肥大
梗塞境界部においてPAS(Periodic Acid Schiff)染色を行い、梗塞境界部の核構造を保持している心筋細胞の短径を測定し、平均化した。この測定を異なる10視野で実施し、平均値を算出した。
v)梗塞境界部における間葉系幹細胞の動員
間葉系幹細胞の表面マーカーであるPDGFRα、CD90、CD105に対する抗体を用いて心筋組織の免疫染色を行い、梗塞境界部に間葉系幹細胞の集積が認められるかを評価した。細胞核の染色はDAPIを用いて行った。
i)心機能
投薬4週間後の心機能評価では、PBS群と比較してHMGB1ペプチド(1-44)群でLVEFが有意に高値であった(図11)。また、投薬4週間後のLVDdおよびLVDsはPBS群よりもHMGB1ペプチド(1-44)群において値が小さく、心拡大の抑制を認めた(図12)。
さらに、LVEFの経時的変化に関しては、PBS群では投薬後、経時的なLVEFの減少を認めたのに対し、HMGB1ペプチド(1-44)群では投薬4週間後まで経時的なLVEFの上昇がみられ、投薬前に対して平均で約7%のLVEFの改善を認めた(図13)。
ii)心筋の線維化
解析の結果、シリウスレッド染色陽性領域の割合はPBS群よりもHMGB1ペプチド(1-44)群の方が有意に小さく、心筋の線維化が抑制されていることが示された(図14)。
iii)血管新生
梗塞境界部におけるvon-Willbrand因子染色の結果、HMGB1ペプチド(1-44)群の方がPBS群よりも有意に血管数が多く(P=0.05)、血管新生が亢進していることが示された(図15)。
iv)心筋細胞の肥大
梗塞境界部におけるPAS染色の結果、HMGB1ペプチド(1-44)群の方がPBS群よりも有意に心筋細胞の短径が小さく(P=0.05)、心筋細胞の肥大化が抑制されることが示された(図16)。
v)梗塞境界部における間葉系幹細胞の動員
心筋組織の免疫染色の結果、PDGFRαおよびCD90の両方が陽性である細胞ならびにPDGFRαおよびCD105の両方が陽性である細胞がHMGB1ペプチド(1-44)群の梗塞境界部近傍に動員されていることが認められた(図17および18)。また、HMGB1ペプチド(1-44)群の梗塞境界部近傍には、PBS群よりも多くのPDGFRα陽性かつCD90陽性の細胞が存在していた(図19)。
高血圧性心筋症に対するHMGB1断片ペプチドの有効性の評価
食塩感受性であるDahl sensitiveラット(以下、DIS/Eisラットとも称する)を実験に用いた。DIS/Eisラットは、高塩分食で飼育すると高血圧となり、高率に心不全を発症するモデルである(例えば生後6週から8%Nacl添加飼料で飼育した場合、生後9週で血圧が250mmHgに達し、生後12週から死亡例が出現し始め、生後16週までに高率で死亡することが確認されている)。
DIS/Eisラット(6週齢、雄、体重約200g、日本SLC)を10匹用意し、高塩分食群(n=7)および低塩分食群(n=3)の2群に分け、前者には8%Nacl添加飼料、後者には0.3%NaCl添加飼料の給餌を15週齢まで継続した。食事以外に関しては自由な運動を妨げるものは一切なくし、ケージ内で飲水、摂食等の制限なく清潔・安静を保って飼育した。
11週齢時において、高塩分食群(n=7)をHMGB1ペプチド(1-44)投与群(n=3)と対照群(n=4)に分け、投与を開始した。被験物質の投与は、PBSを溶媒として1mg/mlの濃度に調整したHMGB1ペプチド(1-44)溶液を3ml/kgの量(ペプチドの投与量としては3mg/kg)で1日1回、4日間連続で尾静脈に注入することにより行った。対照群には、PBSを3ml/kgの量で1日1回、4日間連続で尾静脈に注入した。また、低塩分食群(n=3)も対照群と同様に4日間連続で尾静脈からPBSを投与した。投薬後4週目(15週齢時)に、全身麻酔下に開胸手術を施行してラットの心臓を摘出し、心臓重量の測定を行った後、乳頭筋レベルで左室心筋横断面の組織切片を作製して組織学的解析を行った。
なお、以下において、高塩分食給餌のHMGB1ペプチド(1-44)投与群を「High-1-44群」、高塩分食給餌の対照群を「High-PBS群」、低塩分食群を「Low-PBS群」と省略して表記する。
i)心臓重量
15週齢時に各群のラットから心臓を摘出し、重量を測定した。
ii)心機能および心室の壁厚
投薬前、及び投薬開始後1週間ごとに心エコーを実施し、左室拡張末期径(LVDd)、左室収縮末期径(LVDs)、左室駆出率(LVEF)、拡張末期左室前壁厚(LVAWd)および拡張末期左室後壁厚(LVPWd)を測定、算出した。
iii)心筋の線維化
心筋組織切片をシリウスレッドで染色し、心臓全体または左室の面積に占める染色陽性領域の割合を線維化率(%)として算出した。
i)心臓重量
Low-PBS群と比較して、High-1-44群およびHigh-PBS群は心臓重量が大きかった。また、High-1-44群はHigh-PBS群よりも心臓重量が小さく、HMGB1ペプチド(1-44)の投与により心臓の肥大が抑制されていることが示された(図20)。
ii)心機能
観察期間中、LVEFは、いずれの群においても70%以上の値を維持していた(群間に有意差なし)。
iii)心室の壁厚
観察期間内におけるLVAWdの推移を図21に示す。15週齢時点において、High-PBS群およびHigh-1-44群のLVAWdはLow-PBS群より大きかったが、High-1-44群のLVAWdはHigh-PBS群より小さく、HMGB1ペプチド(1-44)の投与により左室前壁厚の増大が抑制される傾向が見られた。
iv)心筋の線維化
心筋組織切片のシリウスレッド染色の結果を図22に示す。Low-PBS群と比較して、High-PBS群では冠動脈周囲における線維化の亢進が認められた。また、心臓全体に占めるシリウスレッド染色陽性領域の割合(線維化率)はHigh-PBS群よりもHigh-1-44群の方が小さく、HMGB1ペプチド(1-44)の投与によって心筋の線維化が抑制される傾向が見られた(図23A)。左室における線維化率はHigh-PBS群よりもHigh-1-44群の方が小さく、HMGB1ペプチド(1-44)の投与によって心筋の線維化が抑制されていることが示された(図23B)。
高塩分食を給餌したDIS/Eisラットは、高血圧を発症する。また、当該ラットは実際に心肥大および心筋細胞肥大を生じることが確認された。したがって、本実施例で用いた高塩分食給餌DIS/Eisラットは、高血圧性心筋症のモデルであると評価できる。
また、心肥大/心筋細胞肥大は心臓の拡張能の低下をもたらす構造異常である。本実施例で用いた高塩分食給餌DIS/Eisラットは、正常な左室収縮能を維持しつつ、心肥大/心筋細胞肥大を生じていたことから、HFpEFのモデルとしても評価できる。
本発明のHMGB1ペプチド(1-44)は、高塩分食給餌DIS/Eisラットにおいて心肥大および心筋細胞肥大を抑制することから、高血圧性心筋症およびHFpEFの予防および/または治療のために用いることが可能である。
Claims (9)
- 以下の(a)から(c)のいずれかに記載の物質を含有する、心臓の構造異常および/または機能障害を伴う心疾患の予防および/または治療のための医薬組成物:
(a)配列番号:1に記載のアミノ酸配列を含むHMGB1断片ペプチド;
(b)配列番号:1に記載のアミノ酸配列において1若しくは複数個のアミノ酸が置換、欠失、挿入若しくは付加されたアミノ酸配列を含み、且つ、細胞の遊走を刺激する活性を有するペプチド; および
(c)配列番号:1に記載のアミノ酸配列と約80%以上の配列同一性を有するアミノ酸配列を含み、且つ、細胞の遊走を刺激する活性を有するペプチド。 - 心臓の構造異常および/または機能障害を伴う心疾患が、心筋症である、請求項1に記載の医薬組成物。
- 心筋症が、特発性心筋症である、請求項2に記載の医薬組成物。
- 特発性心筋症が、拡張型心筋症、肥大型心筋症、拘束型心筋症および不整脈原性右室心筋症からなる群より選択される、請求項3に記載の医薬組成物。
- 心筋症が、二次性心筋症である、請求項2に記載の医薬組成物。
- 二次性心筋症が、虚血性心筋症、高血圧性心筋症、弁膜症性心筋症、薬剤誘発性心筋症、アルコール性心筋症、ミトコンドリア心筋症、心サルコイドーシスに起因する心筋症、心アミロイドーシスに起因する心筋症、心筋炎に起因する心筋症、筋ジストロフィーに起因する心筋症、心ファブリー病に起因する心筋症、および周産期心筋症からなる群より選択される、請求項5に記載の医薬組成物。
- 心臓の構造異常および/または機能障害を伴う心疾患が、陳旧性心筋梗塞である、請求項1に記載の医薬組成物。
- 以下の(a)から(c)のいずれかに記載の物質を含有する、心筋症または陳旧性心筋梗塞に起因する慢性心不全の予防および/または治療のための医薬組成物:
(a)配列番号:1に記載のアミノ酸配列を含むHMGB1断片ペプチド;
(b)配列番号:1に記載のアミノ酸配列において1若しくは複数個のアミノ酸が置換、欠失、挿入若しくは付加されたアミノ酸配列を含み、且つ、細胞の遊走を刺激する活性を有するペプチド; および
(c)配列番号:1に記載のアミノ酸配列と約80%以上の配列同一性を有するアミノ酸配列を含み、且つ、細胞の遊走を刺激する活性を有するペプチド。 - 以下の(a)から(c)のいずれかに記載の物質を含有する、心筋症または陳旧性心筋梗塞の患者において心拡大、心筋細胞肥大および心筋線維化からなる群より選択される心臓の構造異常を抑制するための医薬組成物:
(a)配列番号:1に記載のアミノ酸配列を含むHMGB1断片ペプチド;
(b)配列番号:1に記載のアミノ酸配列において1若しくは複数個のアミノ酸が置換、欠失、挿入若しくは付加されたアミノ酸配列を含み、且つ、細胞の遊走を刺激する活性を有するペプチド; および
(c)配列番号:1に記載のアミノ酸配列と約80%以上の配列同一性を有するアミノ酸配列を含み、且つ、細胞の遊走を刺激する活性を有するペプチド。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2019008949A MX2019008949A (es) | 2017-01-27 | 2018-01-26 | Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica. |
EP18745136.4A EP3556378A4 (en) | 2017-01-27 | 2018-01-26 | THERAPEUTIC AGENT FOR CARDIOMYOPATHY, OLD MYOCARDINAL INFARM AND CHRONIC HEART FAILURE |
JP2018564639A JP7182162B2 (ja) | 2017-01-27 | 2018-01-26 | 心筋症、陳旧性心筋梗塞および慢性心不全の治療薬 |
BR112019014921-0A BR112019014921A2 (pt) | 2017-01-27 | 2018-01-26 | Agente terapêutico para miocardiopatia, infarto antigo do miocárdio e insuficiência cardíaca crônica |
CN201880008721.3A CN110494154B (zh) | 2017-01-27 | 2018-01-26 | 心肌病、陈旧性心肌梗塞及慢性心力衰竭的治疗剂 |
US16/477,878 US11969459B2 (en) | 2017-01-27 | 2018-01-26 | Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure |
RU2019126796A RU2795320C2 (ru) | 2017-01-27 | 2018-01-26 | Терапевтическое средство для лечения кардиомиопатии, перенесенного инфаркта миокарда и хронической сердечной недостаточности |
KR1020197024762A KR102559262B1 (ko) | 2017-01-27 | 2018-01-26 | 심근증, 진구성 심근경색 및 만성심부전의 치료약 |
CA3051825A CA3051825A1 (en) | 2017-01-27 | 2018-01-26 | Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure |
AU2018213671A AU2018213671B2 (en) | 2017-01-27 | 2018-01-26 | Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017013293 | 2017-01-27 | ||
JP2017-013293 | 2017-01-27 | ||
JP2017151788 | 2017-08-04 | ||
JP2017-151788 | 2017-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018139562A1 true WO2018139562A1 (ja) | 2018-08-02 |
Family
ID=62979422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/002373 WO2018139562A1 (ja) | 2017-01-27 | 2018-01-26 | 心筋症、陳旧性心筋梗塞および慢性心不全の治療薬 |
Country Status (11)
Country | Link |
---|---|
US (1) | US11969459B2 (ja) |
EP (1) | EP3556378A4 (ja) |
JP (1) | JP7182162B2 (ja) |
KR (1) | KR102559262B1 (ja) |
CN (1) | CN110494154B (ja) |
AU (1) | AU2018213671B2 (ja) |
BR (1) | BR112019014921A2 (ja) |
CA (1) | CA3051825A1 (ja) |
MX (1) | MX2019008949A (ja) |
TW (1) | TWI805565B (ja) |
WO (1) | WO2018139562A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020085506A1 (ja) | 2018-10-25 | 2020-04-30 | 国立大学法人大阪大学 | 軟骨疾患の治療薬 |
US11191786B2 (en) | 2009-10-28 | 2021-12-07 | StemRIM Inc. | Agents for promoting tissue regeneration by recruiting bone marrow mesenchymal stem cells and/or pluripotent stem cells into blood |
US11197895B2 (en) | 2008-04-30 | 2021-12-14 | StemRIM Inc. | Method for collecting functional cells in vivo with high efficiency |
US11298403B2 (en) | 2017-12-01 | 2022-04-12 | StemRIM Inc. | Therapeutic agent for inflammatory bowel disease |
JP7495075B2 (ja) | 2019-12-25 | 2024-06-04 | ロート製薬株式会社 | 高血圧性心疾患治療剤 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3051825A1 (en) | 2017-01-27 | 2018-08-02 | StemRIM Inc. | Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure |
KR20190135519A (ko) * | 2017-04-07 | 2019-12-06 | 가부시키가이샤 스템림 | 섬유성 질환의 치료약 |
CN113194978B (zh) * | 2018-10-05 | 2024-03-08 | 斯特姆里姆有限公司 | 具有间充质干细胞的动员活性的肽 |
CN113444692A (zh) * | 2021-06-29 | 2021-09-28 | 上海交通大学医学院附属第九人民医院 | 一种重组心肌细胞及其用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006080434A1 (ja) | 2005-01-27 | 2006-08-03 | Japan Health Sciences Foundation | 間葉系幹細胞を含む細胞シート |
US20080004207A1 (en) * | 2006-02-06 | 2008-01-03 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of hmgb1 for protection against ischemia reperfusion injury |
WO2012147470A1 (ja) | 2011-04-26 | 2012-11-01 | 株式会社ジェノミックス | 組織再生を誘導するためのペプチドとその利用 |
WO2014065347A1 (ja) | 2012-10-25 | 2014-05-01 | 株式会社ジェノミックス | Hmgb1断片を利用した新規心筋梗塞の治療法 |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5238680B2 (ja) | 1972-12-27 | 1977-09-30 | ||
US4732155A (en) | 1985-08-27 | 1988-03-22 | The Children's Medical Center Corporation | Implantable chemoattractant system |
US5658894A (en) | 1989-04-23 | 1997-08-19 | The Trustees Of The University Of Pennsylvania | Compositions for inhibiting restenosis |
US5661127A (en) | 1995-05-01 | 1997-08-26 | The Regents Of The University Of California | Peptide compositions with growth factor-like activity |
JP3018313B2 (ja) | 1996-02-23 | 2000-03-13 | 雪印乳業株式会社 | 骨形成促進及び骨吸収防止剤 |
US6875753B1 (en) | 1996-03-14 | 2005-04-05 | The Governors Of The University Of Alberta | Methods for cell mobilization using in vivo treatment with hyaluronan (HA) |
US20050113335A1 (en) | 1996-04-02 | 2005-05-26 | Pilarski Linda M. | Methods for cell mobilization using in vivo treatment with hyaluronan (HA) |
EP1074268B1 (en) | 1998-03-17 | 2008-01-16 | Chugai Seiyaku Kabushiki Kaisha | Preventives or remedies for inflammatory intestinal diseases containing il-6 receptor antagonist antibodies |
US20040031072A1 (en) | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
ATE440602T1 (de) | 1999-07-28 | 2009-09-15 | Univ Leland Stanford Junior | Nicotinrezeptoragonisten in stammzellen und vorlaüferzellinduktion |
EP1263931A4 (en) | 1999-11-05 | 2009-07-15 | Gerigene Medical Corp | INCREASE AND REPAIR OF IMPERFECTIONS OF SOFT TISSUES RELATED TO AGE |
EP1114862A3 (de) | 1999-11-17 | 2003-08-06 | Switch Biotech Aktiengesellschaft | Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen |
JP2004500095A (ja) | 2000-02-24 | 2004-01-08 | エクサイト セラピーズ, インコーポレイテッド | 細胞の同時の刺激および濃縮 |
JP3421741B2 (ja) | 2000-05-18 | 2003-06-30 | 筑波大学長 | 人工骨髄、血球細胞の増殖方法 |
US20040191246A1 (en) | 2003-02-26 | 2004-09-30 | Connelly Patrick R. | Process for in vivo treatment of specific biological targets in bodily fluid |
ITMI20010562A1 (it) | 2001-03-16 | 2002-09-16 | Marco E Bianchi | Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari |
DE10121254A1 (de) | 2001-04-30 | 2002-11-07 | Switch Biotech Ag | MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind |
WO2002088181A2 (en) | 2001-04-30 | 2002-11-07 | Switch Biotech Ag | Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances |
US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
US7220723B2 (en) | 2001-05-15 | 2007-05-22 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
JP2005512507A (ja) | 2001-05-15 | 2005-05-12 | ノース・ショア−ロング・アイランド・ジューイッシュ・リサーチ・インスティテュート | 抗炎症剤としてのhmgフラグメントの使用 |
ITMI20011986A1 (it) | 2001-09-25 | 2003-03-25 | San Raffaele Centro Fond | Metodo e composizione per l'attivazione di cellule presentanti l'antigene |
CA2467557A1 (en) | 2001-11-19 | 2003-05-30 | Kyowa Hakko Kogyo Co., Ltd. | Agent which mobilizes multipotential stem cells from tissues to peripheral blood |
JP4653952B2 (ja) | 2001-12-07 | 2011-03-16 | サイトリ セラピューティクス インコーポレイテッド | 処理済み脂肪吸引細胞で患者を治療するためのシステムと方法 |
FR2833609B1 (fr) | 2001-12-19 | 2004-12-03 | Natural Implant | Dispositif de prelevement cellulaire ou tissulaire en phase active et utilisations |
WO2004004763A2 (en) | 2002-07-03 | 2004-01-15 | Fondazione Centro San Raffaele Del Monte Tabor | Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
US7553488B2 (en) | 2002-07-05 | 2009-06-30 | UNIVERSITé LAVAL | Antibodies against S100A8 and S100A9 proteins for modulating inflammatory reactions |
AU2003294246A1 (en) | 2002-11-01 | 2004-06-07 | The Board Of Trustees Of The Leland Stanford Junior University | Circulating stem cells and uses related thereto |
GB0226251D0 (en) | 2002-11-11 | 2002-12-18 | San Raffaele Centro Fond | Acetylated protein |
WO2004046345A2 (en) | 2002-11-20 | 2004-06-03 | Critical Therapeutics, Inc. | Use of hmgb fragments as anti-inflammatory agents |
US20040156851A1 (en) | 2002-11-20 | 2004-08-12 | Critical Therapeutics, Inc. | HMGB1 combination therapies |
US7470538B2 (en) | 2002-12-05 | 2008-12-30 | Case Western Reserve University | Cell-based therapies for ischemia |
JP2006517537A (ja) | 2003-01-03 | 2006-07-27 | アルケド バイオテック ゲーエムベーハー | Dna結合タンパク質の使用 |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
CN1193092C (zh) | 2003-03-28 | 2005-03-16 | 浙江大学 | 骨髓间充质干细胞分离和体外扩增培养方法 |
ATE411038T1 (de) | 2003-03-28 | 2008-10-15 | Univ Laval | S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung |
US20090069227A9 (en) | 2003-04-29 | 2009-03-12 | Capogrossi Maurizio C | Use of HMGB1 to promote stem cell migration and/or proliferation |
AU2004242091C1 (en) | 2003-05-07 | 2009-12-24 | La Jolla Institute For Molecular Medicine | Administration of hyaluronic acid to enhance the function of transplanted stem cells |
US20050014255A1 (en) | 2003-05-29 | 2005-01-20 | Board Of Regents, The University Of Texas System | Stem cells for clinical and commercial uses |
US20060183667A1 (en) | 2003-07-11 | 2006-08-17 | Novo Nordisk A/S | Stabilised insulin compositions |
WO2005025604A2 (en) | 2003-09-10 | 2005-03-24 | The General Hospital Corporation | Use of hmgb and hmgb fragments to decrease specific immune response |
CA2538763C (en) | 2003-09-11 | 2015-05-05 | Critical Therapeutics, Inc. | Monoclonal antibodies against hmgb1 |
ITRM20040058A1 (it) | 2004-02-03 | 2004-05-03 | Marco E Bianchi | Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali. |
CA2574548A1 (en) | 2004-07-20 | 2006-01-26 | Fondazione Centro San Raffaele Del Monte Tabor | Use of hmgb1 for wound healing |
MX2007001155A (es) | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
WO2006024547A2 (en) | 2004-09-03 | 2006-03-09 | Creabilis Therapeutics S.P.A. | Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use |
CN102731654A (zh) | 2004-10-22 | 2012-10-17 | 米迪缪尼有限公司 | 抗hmgb1的高亲和力抗体及其用法 |
KR100593397B1 (ko) | 2004-10-27 | 2006-06-28 | 한국원자력연구소 | 중배엽 줄기세포 및/또는 p 물질을 함유하는 상처 치유또는 상처 치유 촉진제, 또는 세포 치료제 |
WO2006047820A1 (en) | 2004-11-01 | 2006-05-11 | Newsouth Innovations Pty Limited | Use of calgranulin a and b in the promotion and inhibition of mineralized tissue formation |
ITRM20050032A1 (it) | 2005-01-21 | 2006-07-22 | Marco E Bianchi | Inibitori ed antagonisti di hmgb1 in grado di inibire la patogenesi e la progressione della malattia aterosclerotica. |
EP1893253B1 (en) | 2005-03-23 | 2010-05-19 | Biosafe S.A. | Integrated system for collecting, processing and transplanting cell subsets, including adult stem cells, for regenerative medicine |
WO2006114805A2 (en) | 2005-04-28 | 2006-11-02 | Fondazione Centro San Raffaele Del Monte Tabor | Use of hmgb2 and hmgb3 proteins for medical applications |
US20100280493A1 (en) | 2005-06-23 | 2010-11-04 | Asha Nayak | Methods and Systems for Treating Injured Cardiac Tissue |
WO2007011606A2 (en) | 2005-07-18 | 2007-01-25 | Critical Therapeutics, Inc. | USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS |
WO2007015546A1 (ja) | 2005-08-04 | 2007-02-08 | Genomix Co., Ltd | 間葉系幹細胞誘導剤及び組織再生促進剤並びに間葉系幹細胞の調製方法 |
WO2007031100A1 (en) | 2005-09-14 | 2007-03-22 | Ostini, Marco | Active immunotherapy of life-threatening systemic inflammation |
WO2007061762A2 (en) | 2005-11-18 | 2007-05-31 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt And Human Services | Non-viral gene delivery complex |
EP1959997A4 (en) | 2005-11-28 | 2009-12-23 | Medimmune Llc | ANTAGONISTS OF HMGB1 AND / OR RAGE AND METHOD OF USE THEREOF |
CA2640087A1 (en) | 2006-01-25 | 2007-08-02 | Mount Sinai School Of Medicine | Methods and compositions for modulating the mobilization of stem cells |
JP4982739B2 (ja) | 2006-06-01 | 2012-07-25 | 国立大学法人 東京医科歯科大学 | ポリグルタミン病の予防・治療剤 |
WO2008018641A1 (en) | 2006-08-11 | 2008-02-14 | Ono Pharmaceutical Co., Ltd. | Monoclonal antibodies against stromal derived factor-1 (sdf-1) |
MX2009002820A (es) | 2006-09-15 | 2009-06-04 | Creabilis Therapeutics Spa | Conjugados polimericos de box-a de hmgb1 y variantes de box-a de hmgb1. |
PL2055308T3 (pl) | 2006-10-30 | 2017-11-30 | Genomix Co., Ltd. | Farmaceutyk do promowania funkcjonalnej regeneracji uszkodzonej tkanki |
CA2629652A1 (en) | 2007-04-24 | 2008-10-24 | Yaojiong Wu | Compositions for preventing or treating skin defects and methods of use thereof |
US8114668B2 (en) | 2007-05-14 | 2012-02-14 | Cardiac Pacemakers, Inc. | Composition for cold storage of stem cells |
KR20160070169A (ko) | 2008-04-30 | 2016-06-17 | 가부시키가이샤 제노믹스 | 생체내 기능적 세포의 고효율 채취법 |
US20110097309A1 (en) | 2008-04-30 | 2011-04-28 | Katsuto Tamai | Pharmaceutical Agent for Promoting the Functional Regeneration of Damaged Tissue |
JP5660889B2 (ja) | 2008-04-30 | 2015-01-28 | 株式会社ジェノミックス | 末梢循環への骨髄由来多能性幹細胞動員薬 |
JP2013508013A (ja) | 2009-10-16 | 2013-03-07 | ザ ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー | 細胞療法戦略を用いた慢性神経組織損傷の治療方法 |
CA2773356A1 (en) | 2009-10-20 | 2011-04-28 | Maine Medical Center | Compositions and methods for treating inflammation and fibrosis |
US11191786B2 (en) | 2009-10-28 | 2021-12-07 | StemRIM Inc. | Agents for promoting tissue regeneration by recruiting bone marrow mesenchymal stem cells and/or pluripotent stem cells into blood |
WO2011092285A2 (en) * | 2010-01-29 | 2011-08-04 | Metanomics Gmbh | Means and methods for diagnosing heart failure in a subject |
CN102247392A (zh) * | 2010-05-21 | 2011-11-23 | 中国医学科学院药物研究所 | 甘草酸治疗扩张型心肌病心脏重构和心功能障碍的用途 |
JP5950428B2 (ja) | 2010-08-05 | 2016-07-13 | 日東電工株式会社 | 線維化組織から正常組織を再生するための組成物 |
CA2810851C (en) | 2010-09-09 | 2022-08-02 | University Of Southern California | Compositions and methods for the removal of biofilms comprising a high-mobility group-box (hmg-box) domain containing polypeptide |
CN102443064A (zh) | 2011-11-03 | 2012-05-09 | 刘誉 | 一种基于凝血酶活性的双靶向作用的嵌合多肽及其应用 |
WO2014016417A1 (en) | 2012-07-26 | 2014-01-30 | Ospedale San Raffaele Srl | Hmgb1 variants and uses thereof |
KR101448800B1 (ko) | 2012-10-24 | 2014-10-13 | 한양대학교 산학협력단 | 핵산 전달 복합체 |
WO2014065348A1 (ja) | 2012-10-25 | 2014-05-01 | 株式会社ジェノミックス | Hmgb1断片を利用した脊髄の損傷に対する新規治療法 |
GB2514424A (en) * | 2013-05-25 | 2014-11-26 | Univ Dublin | Therapies for Cardiomyopathy |
KR101636139B1 (ko) | 2013-08-28 | 2016-07-06 | 가톨릭대학교 산학협력단 | 면역조절능이 우수한 sRAGE 과발현 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 |
GB201508337D0 (en) | 2015-05-15 | 2015-06-24 | Hmgbiotech S R L | Novel peptides |
CA3051825A1 (en) | 2017-01-27 | 2018-08-02 | StemRIM Inc. | Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure |
KR20190135519A (ko) | 2017-04-07 | 2019-12-06 | 가부시키가이샤 스템림 | 섬유성 질환의 치료약 |
JPWO2019107530A1 (ja) | 2017-12-01 | 2020-11-26 | 株式会社ステムリム | 炎症性腸疾患の治療薬 |
JPWO2019107566A1 (ja) | 2017-12-01 | 2020-12-03 | 株式会社ステムリム | 外胚葉性間葉系幹細胞およびその製造方法 |
WO2019156137A1 (ja) | 2018-02-08 | 2019-08-15 | 株式会社ステムリム | 乾癬の治療薬 |
CN113194978B (zh) | 2018-10-05 | 2024-03-08 | 斯特姆里姆有限公司 | 具有间充质干细胞的动员活性的肽 |
WO2020071519A1 (ja) | 2018-10-05 | 2020-04-09 | 株式会社ステムリム | 間葉系幹細胞の動員に基づく疾患治療薬 |
JPWO2020158924A1 (ja) | 2019-01-31 | 2021-12-02 | 国立大学法人大阪大学 | 母児間免疫寛容を誘導する方法 |
JPWO2021020509A1 (ja) | 2019-07-31 | 2021-02-04 | ||
BR112022019434A2 (pt) | 2020-04-03 | 2022-12-06 | Stemrim Inc | Peptídeo que tem atividade de mobilização de células-tronco mesenquimais |
-
2018
- 2018-01-26 CA CA3051825A patent/CA3051825A1/en active Pending
- 2018-01-26 MX MX2019008949A patent/MX2019008949A/es unknown
- 2018-01-26 CN CN201880008721.3A patent/CN110494154B/zh active Active
- 2018-01-26 EP EP18745136.4A patent/EP3556378A4/en active Pending
- 2018-01-26 BR BR112019014921-0A patent/BR112019014921A2/pt unknown
- 2018-01-26 US US16/477,878 patent/US11969459B2/en active Active
- 2018-01-26 WO PCT/JP2018/002373 patent/WO2018139562A1/ja unknown
- 2018-01-26 AU AU2018213671A patent/AU2018213671B2/en active Active
- 2018-01-26 JP JP2018564639A patent/JP7182162B2/ja active Active
- 2018-01-26 TW TW107102933A patent/TWI805565B/zh active
- 2018-01-26 KR KR1020197024762A patent/KR102559262B1/ko active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006080434A1 (ja) | 2005-01-27 | 2006-08-03 | Japan Health Sciences Foundation | 間葉系幹細胞を含む細胞シート |
US20080004207A1 (en) * | 2006-02-06 | 2008-01-03 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of hmgb1 for protection against ischemia reperfusion injury |
WO2012147470A1 (ja) | 2011-04-26 | 2012-11-01 | 株式会社ジェノミックス | 組織再生を誘導するためのペプチドとその利用 |
WO2014065347A1 (ja) | 2012-10-25 | 2014-05-01 | 株式会社ジェノミックス | Hmgb1断片を利用した新規心筋梗塞の治療法 |
Non-Patent Citations (6)
Title |
---|
FUKUSHIMA ET AL.: "Registry Report on Heart Transplantation in Japan (June 2016", CIRCULATION JOURNAL, 6 January 2017 (2017-01-06) |
ISHIKANE SHIN: "Development of multi-growth factor secreted fetal membrane-derived mesenchymal stem cell sheets", GRANTS-IN-AID FOR SCIENTIFIC RESEARCH, RESEARCH REPORT, 11 June 2014 (2014-06-11) |
J BIOCHEM., vol. 134, no. 2, August 2003 (2003-08-01), pages 269 - 76 |
LUND ET AL.: "The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant", J HEART LUNG TRANSPLANT., vol. 35, no. 10, October 2016 (2016-10-01), pages 1158 - 1169, XP029779516, DOI: 10.1016/j.healun.2016.08.017 |
NARUMI T. ET AL.: "High-mobility group box 1 attenuates mitochondrial dysfunction and apoptosis via heat shock protein beta 1 induction in doxorubicin-induced cardiomyopathy", BULLETIN OF YAMAGATA UNIVERSITY (MEDICAL SCIENCE), vol. 33, no. 2, 2015, pages 126 - 127, XP055615521 * |
TAAHASHI ET AL: "Effects of HMGB1 on Chronic renal failure after infarction - New mechanism for curative effect in cell therapy", ACTA CARDIOLOGICA PAEDIATRICA JAPONICA, vol. 27, 2011, pages S189, I - E-19, XP9515651 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11197895B2 (en) | 2008-04-30 | 2021-12-14 | StemRIM Inc. | Method for collecting functional cells in vivo with high efficiency |
US11191786B2 (en) | 2009-10-28 | 2021-12-07 | StemRIM Inc. | Agents for promoting tissue regeneration by recruiting bone marrow mesenchymal stem cells and/or pluripotent stem cells into blood |
US11298403B2 (en) | 2017-12-01 | 2022-04-12 | StemRIM Inc. | Therapeutic agent for inflammatory bowel disease |
WO2020085506A1 (ja) | 2018-10-25 | 2020-04-30 | 国立大学法人大阪大学 | 軟骨疾患の治療薬 |
KR20210082478A (ko) | 2018-10-25 | 2021-07-05 | 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 | 연골 질환의 치료약 |
JP7495075B2 (ja) | 2019-12-25 | 2024-06-04 | ロート製薬株式会社 | 高血圧性心疾患治療剤 |
Also Published As
Publication number | Publication date |
---|---|
TWI805565B (zh) | 2023-06-21 |
AU2018213671B2 (en) | 2024-06-06 |
CN110494154A (zh) | 2019-11-22 |
RU2019126796A (ru) | 2021-03-01 |
TW201832776A (zh) | 2018-09-16 |
US20190343924A1 (en) | 2019-11-14 |
JP7182162B2 (ja) | 2022-12-02 |
AU2018213671A1 (en) | 2019-08-08 |
BR112019014921A2 (pt) | 2020-03-31 |
CA3051825A1 (en) | 2018-08-02 |
US11969459B2 (en) | 2024-04-30 |
RU2019126796A3 (ja) | 2021-05-26 |
JPWO2018139562A1 (ja) | 2019-11-14 |
EP3556378A4 (en) | 2020-11-18 |
KR20190122212A (ko) | 2019-10-29 |
KR102559262B1 (ko) | 2023-07-25 |
EP3556378A1 (en) | 2019-10-23 |
CN110494154B (zh) | 2023-09-29 |
MX2019008949A (es) | 2019-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018139562A1 (ja) | 心筋症、陳旧性心筋梗塞および慢性心不全の治療薬 | |
JP5710709B2 (ja) | ヒト骨髄由来内皮前駆細胞の同定、及び虚血性傷害後の心筋細胞の機能を改善するためのヒト骨髄由来内皮前駆細胞の使用 | |
AU2013335684B2 (en) | Novel method for treating cardiac infarction using HMGB1 fragment | |
JP5968442B2 (ja) | 心筋梗塞の修復再生を誘導する多能性幹細胞 | |
JP6061345B2 (ja) | 心臓修復のための骨髄由来cd271前駆細胞 | |
JP6253590B2 (ja) | Hmgb1断片を利用した脊髄の損傷に対する新規治療法 | |
JP7091427B2 (ja) | 心不全の治療方法 | |
JP2005206544A (ja) | 筋肉再生剤 | |
JP6570053B2 (ja) | スフィンゴシン−1−リン酸受容体2活性化化合物含有非傷害部位投与製剤 | |
RU2795320C2 (ru) | Терапевтическое средство для лечения кардиомиопатии, перенесенного инфаркта миокарда и хронической сердечной недостаточности | |
WO2021045190A1 (ja) | 心筋炎の治療剤 | |
WO2016161462A1 (en) | Ischemic tolerant mesenchymal stem cells and their factors in the treatment of cardiovascular conditions | |
JP2019127463A (ja) | Muse細胞動員剤及び心筋障害への利用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18745136 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018564639 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3051825 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019014921 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2018213671 Country of ref document: AU Date of ref document: 20180126 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018745136 Country of ref document: EP Effective date: 20190718 |
|
ENP | Entry into the national phase |
Ref document number: 20197024762 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112019014921 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190719 |